%0 Journal Article
%A Beier, Dagmar
%A Proescholdt, Martin
%A Reinert, Christiane
%A Pietsch, Torsten
%A Jones, David
%A Pfister, Stefan
%A Hattingen, Elke
%A Seidel, Clemens
%A Dirven, Linda
%A Luerding, Ralf
%A Reijneveld, Jaap
%A Warmuth-Metz, Monika
%A Bonsanto, Matteo
%A Bremer, Michael
%A Combs, Stephanie E
%A Rieken, Stefan
%A Herrlinger, Ulrich
%A Kuntze, Holger
%A Mayer-Steinacker, Regine
%A Moskopp, Dag
%A Schneider, Thomas
%A Beringer, Andreas
%A Schlegel, Uwe
%A Stummer, Walter
%A Welker, Helmut
%A Weyerbrock, Astrid
%A Paulsen, Frank
%A Rutkowski, Stefan
%A Weller, Michael
%A Wick, Wolfgang
%A Kortmann, Rolf-Dieter
%A Bogdahn, Ulrich
%A Hau, Peter
%T Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
%J Neuro-Oncology
%V 20
%N 3
%@ 1523-5866
%C Oxford
%I Oxford Univ. Press
%M DKFZ-2018-00152
%P 400 - 410
%D 2018
%X Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the feasibility of radiochemotherapy exist. The German Neuro-Oncology Working Group (NOA) performed a prospective descriptive multicenter single-arm phase II trial to evaluate feasibility and toxicity of radio-polychemotherapy.The NOA-07 trial combined craniospinal irradiation with vincristine, followed by 8 cycles of cisplatin, lomustine, and vincristine. Adverse events, imaging and progression patterns, histological and genetic markers, health-related quality of life (HRQoL), and cognition were evaluated. Primary endpoint was the rate of toxicity-related treatment terminations after 4 chemotherapy cycles, and the toxicity profile. The feasibility goal was reached if at least 45
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29016837
%2 pmc:PMC5817955
%R 10.1093/neuonc/nox155
%U https://inrepo02.dkfz.de/record/132464